[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 8 sources · 7 days · First seen · Last updated

DocMorris financial performance and growth

Overview

DocMorris AG has reported strong growth for the first half of 2026, leading the company to raise its full-year guidance for revenue and adjusted EBITDA. External revenue rose 12.5% year-on-year to CHF 627.8 million, driven by a 38.3% increase in prescription business and a 71.4% surge in digital services. The company expects to reach EBITDA breakeven during the second half of 2026, with adjusted EBITDA losses narrowing to between CHF 10 million and CHF 17.5 million.

Subsequent reports indicate an operational turnaround, with revenue growth reaching 13.2% to 295.4 million CHF. This growth is largely attributed to a 45.8% surge in the prescription business, with Germany remaining the strongest market. The company has successfully reduced losses, with adjusted EBITDA improving from minus 28.8 million CHF to minus 10.9 million CHF during the first semester.

Entities

DocMorris · InnoCan Pharma · Walter Hess · Redcare Pharmacy · Daniel Wüest

Timeline

  1. 18 days ago

    [BUSINESS] 3 sources
    InnoCan Pharma and DocMorris report divergent financial trends

    InnoCan Pharma reports 29.7% revenue growth despite stock price declines, while DocMorris sees a turnaround driven by a 45.8% surge in its prescription drug business.

  2. 24 days ago

    [BUSINESS] 7 sources
    DocMorris raises 2026 guidance following strong H1 growth

    DocMorris AG raised its 2026 guidance following strong first-half growth in prescription drugs and digital services, aiming for EBITDA breakeven in the second half of the year.

Sources

ad-hoc-news.de · biotech-investments.com · etailment.de · finanzen.ch · finanzen.net · finanznachrichten.de · it-boltwise.de · kapitalmarktexperten.de